

CURRICULUM VITAE



Prof. Dr. med. Uwe Platzbecker

Professor for Translational Hematology
Medizinische Klinik und Poliklinik I
Medizinische Fakultät Carl Gustav Carus
Technische Universität Dresden
Fetscherstrasse 74, D-01307 Dresden
Phone: 0351 458 2583, Fax: 0351 458 4347
Email: uwe-platzbecker@uniklinikum-dresden.de

Webpages Research Group: www.mds-dresden.de
www.emsco.eu
www.sfb655.de

Summary biography

After graduating from medical school in 1996, I first started medical training in heart surgery. Since 1998, I have been working at the Department of Hematology and Oncology at the University Hospital “Carl Gustav Carus” in Dresden, Germany. Between 2001 and 2003 I completed a 2-year Postdoctoral Fellowship provided by the Humboldt-foundation at the Fred Hutchinson Cancer Research Center in Seattle, USA. Since 2012, I hold a position of a Professor of Hematology at the University Hospital “Carl Gustav Carus” in Dresden and I am the Head of the section of hematology as well as chair of the medical ethics committee of the TU Dresden. In 2015 I was appointed as Transcampus Professor of Hematology at the Faculty of Life Science and Medicine at King’s College London.

My clinical expertise lies in hematological malignancies with a focus on MDS and AML. The main scientific interest involves the translational exploration of innovative treatment options for these patients involving the use of allogeneic hematopoietic stem cell transplantation. I am a member of the steering committee of the SAL study and German MDS group. In 2012 I have co-founded the European MDS Study Coordinating Office (EMSCO).

Education and training

INSTITUTION	DEGREE / CERTIFICATE	YEAR	FIELD OF STUDY / DISCIPLINE
University Hospital “Carl Gustav Carus” at the TU Dresden	Final degree in Medicine (“Staatsexamen”)	1996	Medicine
University Hospital “Carl Gustav Carus” at the TU Dresden	MD	1997	Medicine
Fred Hutchinson Cancer Research Center, Seattle	Postdoctoral	2002	Medicine / translational research
University Hospital “Carl Gustav Carus” at the TU Dresden	Board certification	2005	Internal Medicine
University Hospital “Carl Gustav Carus” at the TU Dresden	Board certification	2007	Hematology / Oncology
University Hospital “Carl Gustav Carus” at the TU Dresden	Board certification	2008	Palliative Medicine
University Hospital “Carl Gustav Carus” at the TU Dresden	Board certification	2008	Hemostaseology

Positions and honors

Positions and Employment

Since 2015	Appointment as Transcampus Professor of Hematology at the Faculty of Life Science and Medicine at King's College London (UK)
Since 2014	Head of the section of hematology, Dept. of Internal Medicine I, University Hospital "Carl Gustav Carus" at the TU Dresden
Since 2012	Appointment as Professor of Translational Hematology (W2), TU Dresden
2006	Habilitation (Privatdozent)
2005	Senior physician and Head of Hematology out-patient department, Dept. of internal Medicine I, University Hospital "Carl Gustav Carus" at the TU Dresden
Since 2002	Dept. of internal Medicine I, University Hospital "Carl Gustav Carus", at the TU Dresden
2001-2002	Postdoc supported by the Humboldt-Foundation (Feodor Lynen Project) at the Fred Hutchinson Cancer Research Center, Prof. Dr. Deeg, Seattle, USA
1998-2001	Dept. of internal Medicine I, University Hospital "Carl Gustav Carus" at the TU Dresden
1998	Medical practice for Radiology, Grosche/Hupke/Lautenbach, Dresden
1996-1998	Heart Center Dresden, Clinic for Cardio-and Thoracic Vascular Surgery, TU Dresden

Other Experience and Professional Memberships

Professional appointments:

Since 2014	Chair medical ethics committee of the TU Dresden
Since 2013	Chairman European MDS studies coordination office (EMSCO) by the ELN
Since 2012	Co-Chairman MDS EHA SWG (Chair: P. Fenaux)

Memberships:

Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)
American Society of Hematology (ASH)
European Haematology Association (EHA)
Study Alliance Leukemia (SAL)
Deutsch-Österreichisch-Schweizerische MDS Studiengruppe (DACH)
European Leukemia Net (ELN)
Gesellschaft für Thrombose und Hämostaseologie (GTH)

Honors

2014	EHA educational presentation
2013	ASH educational presentation
2012	Poster award, DGHO
2010	Best Abstract, European Leukemia Net meeting
2009	Poster award, 10 th International Symposium on MDS
2006	Travel award, American Society of Hematology (ASH)
2006	Chugai Science Award

Recent and currently conducted clinical trials (selection)

Indication	Short title	Groups	Protocol information
MDS	VIDAZA-ALLO	German MDS SG	Comparison of treatment with 5-azacitidine and 5-azacitidine followed by allogenic SCT in elderly patients with MDS depending on donor availability
MDS	PACE	German MDS SG	An open prospective trial for the assessment of the long term effect of ACE-536 on the treatment of anemia in patients with low risk MDS
CMML	DACOTA	German MDS SG Italian MDS SG French MDS SG	A randomized phase III study of decitabine with or without hydroxyurea vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia
MDS	EUROPE	German MDS SG French MDS SG	Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia
MDS or AML	RELAZA2	SAL (Germany)	Treatment of imminent hematological relapse in patients with AML and MDS following allogeneic SCT with 5-azacitidine
AML or MDS	ALLIVE	German MDS SG	Assessment of body, liver and labile plasma iron and their importance for prognosis and immune reconstitution of patients with AML or MDS after allogeneic SCT
APL	Napoleon	SAL (Germany and Czech republic)	National acute promyelocytic leukemia (APL) observational study. NAPOLEON-Registry of the German AML Intergroup
APL	APOLLO	SAL (Germany) GIMEMA (Italy) French APL group HOVON (Netherlands)	A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia

Contributions to Science

Author or co-author of more than 180 scientific publications in peer-reviewed journals.

Further activities in the scientific community include reviewer activities for several journals including Blood, Lancet, Leukemia, PLOS and Haematologica and in 2013 I have been appointed as section editor for Leukemia.

Grant reviews have been carried out for the following institutions: Deutsche José Carreras Leukämie-Stiftung e.V., Leukaemia & Lymphoma Research Council (LLR, UK), Spanish Research Council (Spain) and Swiss National Science Foundation (SNSF).

Complete list of published work:

<http://www.ncbi.nlm.nih.gov/pubmed/?term=platzbecker+U>

Publications

1. Key figures:

> 180 Publications

Hirsch factor: 30

2. Complete list of published work:

<http://www.ncbi.nlm.nih.gov/pubmed/?term=platzbecker+U>

3. Six most important publications

1: **Platzbecker U**, Wong RM, Verma A, Abboud C, Araujo S, Chiou T, Feigert H, Yeh S, Götze K, Gorin N, Greenberg P, Kambhampati S, Kim Y, Lee J, Lyons R, Ruggeri M, Santini V, Cheng G, Jang C, Chen C, Johnson B, Bennett J, Mannino F, Kamel Y, Stone N, Dougherty S, Chan G, Giagounidis A. Placebo-controlled, randomized phase 1/2 trial of the thrombopoietin receptor agonist eltrombopag versus placebo in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myeloid leukaemia. *Lancet haematology* 2015, in press

2: Bulycheva E, Rauner M, Medyouf H, Theurl I, Bornhäuser M, Hofbauer LC, **Platzbecker U**. Myelodysplasia is in the niche: novel concepts and emerging therapies. *Leukemia*. 2015 Feb;29(2):259-68. doi: 10.1038/leu.2014.325. Epub 2014 Nov 14. Review. PubMed PMID: 25394715; PubMed Central PMCID: PMC4320287.

3: Ferrer RA, Wobus M, List C, Wehner R, Schönefeldt C, Brocard B, Mohr B, Rauner M, Schmitz M, Stiehler M, Ehninger G, Hofbauer LC, Bornhäuser M, **Platzbecker U**. Mesenchymal stromal cells from patients with myelodysplastic syndrome display distinct functional alterations that are modulated by lenalidomide. *Haematologica*. 2013 Nov;98(11):1677-85. doi: 10.3324/haematol.2013.083972. Epub 2013 May 28. PubMed PMID: 23716561; PubMed Central PMCID: PMC3815166.

4: Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, **Platzbecker U**; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. *N Engl J Med*. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874. PubMed PMID: 23841729.

5: **Platzbecker U**, Bräulke F, Kündgen A, Götze K, Bug G, Schönefeldt C, Shirneshan K, Röllig C, Bornhäuser M, Naumann R, Neesen J, Giagounidis A, Hofmann WK, Ehninger G, Germing U, Haase D, Wermke M. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. *Leukemia*. 2013 Jun;27(6):1403-7. doi: 10.1038/leu.2013.26. Epub 2013 Jan 28. PubMed PMID: 23354011; PubMed Central PMCID: PMC3677141.

6: **Platzbecker U**, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut IM, Knoth H, Röllig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornhäuser M, Thiede C. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. *Leukemia*. 2012 Mar;26(3):381-9. doi: 10.1038/leu.2011.234. Epub 2011 Sep 2. PubMed PMID: 21886171; PubMed Central PMCID: PMC3306138.